Pharmacological characterization of the pathway involved in the insulin-induced release of a platelet-derived relaxing factor. (a) Effect of the guanylyl cyclase inhibitor, NS 2028 (NS, 10 μmol/L, 30 min), and the G kinase inhibitors, KT 5823 (KT, 1 μmol/L, 30 min) and Rp-8CPT-cGMPs (Rp, 10 μmol/L, 30 min), on the insulin (1 μmol/L, 10 min)-induced release of a relaxing factor from washed human platelets, i.e., inhibitors applied to the platelet donor and the detector artery ring compared with the effects observed when the inhibitors were applied only to the detector ring. (b) Statistical summary showing the effect of L-NA (300 μmol/L, 30 min), diclofenac (Dl, 10 μmol/L, 30 min), the phospholipase A2 inhibitor AACOCF3 (AA, 3 μmol/L, 30 min), and the adenylyl cyclase inhibitor 2′,3′-dideoxyadenosine (DDA, 100 μmol/L, 30 min) on the insulin (1 μmol/L, 10 min)-induced release of a relaxing factor from washed human platelets. (c) Summary showing the effect of the AMPK inhibitor iodotubercidin (Iodo, 1 μmol/L, 30 min) and the phosphatidylinositol 3-kinase inhibitor wortmannin (Wort, 40 nmol/L, 30 min) on the insulin (1 μmol/L, 10 min)-induced release of a relaxing factor from washed human platelets. The results shown represent the mean ± SEM of data obtained in five to seven independent experiments. **P < 0.01 and ***P < 0.001 versus the response obtained using the supernatant from unstimulated platelets (Sol).